BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35166084)

  • 1. Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients.
    Ahn HJ; Byun JM; Kim I; Youk J; Koh Y; Shin DY; Hong J; Yoon SS
    J Korean Med Sci; 2022 Feb; 37(6):e48. PubMed ID: 35166084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
    Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
    N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag.
    Tang C; Chen F; Kong D; Ma Q; Dai H; Yin J; Li Z; Chen J; Zhu X; Mao X; Wu D; Tang X
    J Hematol Oncol; 2018 Aug; 11(1):103. PubMed ID: 30115080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
    Giammarco S; Sica S; Chiusolo P; Laurenti L; Sorá F; Martino M; Metafuni E; Busca A; Risitano A; Vallejo C; Bacigalupo A
    Int J Hematol; 2021 Aug; 114(2):228-234. PubMed ID: 33886103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.
    Gao F; Zhou X; Shi J; Luo Y; Tan Y; Fu H; Lai X; Yu J; Huang H; Zhao Y
    Ann Hematol; 2020 Nov; 99(11):2679-2687. PubMed ID: 32519094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
    Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
    Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
    Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children.
    Uria-Oficialdegui ML; Alonso L; Benitez-Carabante MI; Renedo B; Oliveras M; Diaz-de-Heredia C
    Pediatr Transplant; 2021 Jun; 25(4):e14010. PubMed ID: 33742757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment of secondary graft failure after allogeneic stem cell transplantation for aplastic anemia with eltrombopag].
    Takano K; Izumi T; Kawamura T; Horiuchi T; Kobayashi S; Sato K; Kimura F
    Rinsho Ketsueki; 2022; 63(3):177-181. PubMed ID: 35387929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
    Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
    Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
    Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
    Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
    Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
    Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
    [No Abstract]   [Full Text] [Related]  

  • 13. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
    Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
    Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation.
    Fu H; Zhang X; Han T; Mo X; Wang Y; Chen H; Han W; Wang J; Wang F; Yan C; Zhang Y; Sun Y; Liu K; Huang X; Xu L
    Bone Marrow Transplant; 2019 Aug; 54(8):1310-1318. PubMed ID: 30664724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
    Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
    Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
    Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
    Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
    Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag Add-on Treatment in a Child With Fanconi Aplastic Anemia Awaiting Hematopoietic Stem Cell Transplantation.
    Aydin Koker S; Çalişkan Polat A
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e74-e76. PubMed ID: 33560087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation.
    Nampoothiri RV; Ho L; McEwan C; Pasic I; Lam W; Law AD; Michelis FV; Thyagu S; Kim DDH; Gerbitz A; Viswabandya A; Lipton JH; Mattsson J; Kumar R
    Bone Marrow Transplant; 2021 Oct; 56(10):2471-2476. PubMed ID: 34108675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
    Huan Ng C; Jang-Milligan F; Schultz KR
    Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.